-
Day after night! China's vaccine research and development to provide strong support for the fight against epidemic prevention and control
Time of Update: 2020-06-16
Medicine Network June 11 - China's five have been approved to carry out clinical trials of the new coronavirus vaccine, is expected to complete the second phase of clinical trials in July this year T
-
287 large varieties or band purchases
Time of Update: 2020-06-15
According to the Jinhua Medical Insurance Bureau official micro-release news, recently, Jinhua City Medical Insurance Bureau organized the second batch of drug belt procurement work meeting, becoming
-
FDA has granted Annamycin fast-track eligibility to treat AML
Time of Update: 2020-06-10
recently, Moleculin Biotech (http:// announced that the U.S FDA (http:// has granted Annamycin (Anamamycin) fast-track eligibility to treat recurrent or refractory acute myeloid leukemia (AML)
-
FDA approves 6-price vaccine Vaxelis for 6-week-old son to 4-year-old
Time of Update: 2020-06-10
recently, Sanofi announced that the U.S Food and Medicines (http:// Administration ( FDA (http:// ) has approved vaxelis, a liquid-all-liquid, ready-to-use six-in-one vaccine for children betwee
-
Israel's Vaxival Bios develops cancer vaccine "ImMucin" to stop cancer recurrence
Time of Update: 2020-06-09
Recent lying news emerged that http:// an Israeli biotech company, had developed a revolutionary cancer vaccine, ImMucin, Vaxil Bios, specifically designed to prevent a recurrence after cancer tre
-
Rohingya Pharmaceuticals cephalosporine capsules approved by the State Drug Administration
Time of Update: 2020-06-09
recently, Shandong Luoxin Pharmaceutical Group Limited Company (http:// (hereinafter referred to as "Roxin Pharmaceuticals") cephalosporine capsules were approved by the State Pharmaceutical (h
-
FDA approves Reblozyl (luspatercept-aamt) for treatment of beta thalassemia in adults
Time of Update: 2020-06-07
The u.S Food Drug (http:// Administration ( FDA (http:// ) recently approved Reblozyl (luspatercept-aamt) for the treatment of beta thalassemia in adults About Reblozyl Reblozyl is an innovat
-
2012 Second International Forum on Medicine held in Dandong
Time of Update: 2020-06-04
Business Agency, June 19 - The Second International Forum on Medicine, entitled "Promoting Manchu Traditional Medicine Culture to Promote the Development of Manchu Pharmaceutical Industry", was held
-
China's self-developed H7N9 avian influenza vaccine into clinical trials
Time of Update: 2020-06-03
Business Association March 4 - National Committee of the Chinese People's Political Consultative Conference (CPPCC) member, Chinese Academy of Engineering academician Li Lanxuan said that China's s
-
Boya biological declared clinical class 1 biological products for treatment of HFMD (EV71) human immunoglobulin accepted
Time of Update: 2020-04-03
According to the information on July 2 on the website of the State Food and Drug Administration (CFDA), the human immunoglobulin of class 1 therapeutic biological product hand foot mouth disease (EV71
-
Class 3.1 new drug of shisiyao: roflust tablet approved for clinical use
Time of Update: 2020-04-03
Shijiazhuang No.4 Pharmaceutical Co., Ltd announced that it has obtained the approval documents of clinical trials of rofluoristone tablets from the State Food and drug administration Rofluorostat is
-
11 provinces to open medical supplies negotiations by the end of September
Time of Update: 2020-03-20
Pharmaceutical Network Industry Dynamics , recently, the National Health Insurance Administration issued a letter urging the provinces in April to do a good job in the second batch of load purchase w
-
R & D Daily: anstelai invests heavily in general car / tcr-t cell therapy
Time of Update: 2020-01-16
Estella has invested heavily in general car / tcr-t cell therapy; 204 varieties have passed / deemed to pass the consistency evaluation; Keya medical artificial intelligence medical imaging products h
-
The first bevacizumab bio similar drug in China, Qilu pharmaceutical can be approved for marketing
Time of Update: 2019-12-09
On December 9, the State Drug Administration approved the application for listing and registration of bevacizumab injection (trade name: antake) developed by Qilu Pharmaceutical Co., Ltd It is the fir
-
Breakthrough therapy label has become the wind vane of drug approval: the probability of approval is up to 45
Time of Update: 2019-12-03
Author: 1 ° C On November 14, 2019, bukinsa, a global innovative drug of Baiji, was approved by FDA, indicating recurrent / refractory mantle cell lymphama Zebotinib has set many records, fast track,
